


Formula II

or a pharmaceutically acceptable salt thereof,

- wherein Y is O, NH, or N-(C1-C4 alkyl);
- wherein Z is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (C1-C6)-alkyl or (C2-C6)-alkenyl, or



- wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl;
- wherein T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or O-(C2-C4)-alkenyl and carbonyl;
- wherein Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having one to three substituents which are independently selected from the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

group consisting of hydrogen, halo, hydroxyl, nitro, CF₃, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-(C2-C4)-straight or branched alkenyl, O-benzyl, O-phenyl, amino and phenyl;

- wherein R₁ is U; X is either oxygen or CH-U, provided that if R₁ is hydrogen, then X is CH-U, or if X is oxygen then R₁ is U;

- wherein U is hydrogen, O-(C1-C4)-straight or branched alkyl or O-(C2-C4)-straight or branched alkenyl, C1-C6-straight or branched alkyl, or C2-C6-straight or branched alkenyl, C5-C7-cycloalkyl or (C5-C7)-cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar;

- wherein J is hydrogen or C1 or C2 alkyl or benzyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylethyl; or wherein J and K may be taken together to form a 5 membered heterocyclic ring which may contain an oxygen (O), sulfur (S), SO or SO₂ substituted therein; and


- wherein said neurological activity does not include amyotrophic lateral sclerosis.

25. A method for promoting neuronal regeneration and/or growth in an animal, comprising:

administering to said animal an effective amount of compound having an affinity for FKBP-type immunophilins according to formula II

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP


1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



Formula II

or a pharmaceutically acceptable salt thereof,

- wherein Y is O, NH, or N-(C1-C4 alkyl);
- wherein Z is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (C1-C6)-alkyl or (C2-C6)-alkenyl, or



- wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl;
- wherein T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or O-(C2-C4)-alkenyl and carbonyl;
- wherein Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having one to three substituents which are independently selected from the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

group consisting of hydrogen, halo, hydroxyl, nitro, CF₃, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-(C2-C4)-straight or branched alkenyl, O-benzyl, O-phenyl, amino and phenyl;

- wherein R₁ is U; X is either oxygen or CH-U, provided that if R₁ is hydrogen, then X is CH-U, or if X is oxygen then R₁ is U;

- wherein U is hydrogen, ~~O-(C1-C4)-straight or branched alkyl or O-(C2-C4)-straight or branched alkenyl~~, C1-C6-straight or branched alkyl, or C2-C6-straight or branched alkenyl, C5-C7-cycloalkyl or (C5-C7)-cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; and

- wherein J is hydrogen or C1 or C2 alkyl or benzyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylethyl; or wherein J and K may be taken together to form a 5 membered heterocyclic ring which may contain an oxygen (O), sulfur (S), SO or SO₂ substituted therein.


33. A method for stimulating the growth of at least one damaged peripheral nerve, comprising:

administering to said damaged peripheral nerve an effective amount of a compound having an affinity for FKBP-type immunophilins according to formula II

D3

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP


1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



Formula II

or a pharmaceutically acceptable salt thereof,

- wherein Y is O, NH, or N-(C1-C4 alkyl);
- wherein Z is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (C2-C6)-alkyl or alkenyl, or



- wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl;
- wherein T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or O-(C2-C4)-alkenyl and carbonyl;
- wherein Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having one to three substituents which are independently selected from the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

group consisting of hydrogen, halo, hydroxyl, nitro, CF₃, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-(C2-C4)-straight or branched alkenyl, O-benzyl, O-phenyl, amino and phenyl;

- wherein R₁ is U; X is either oxygen or CH-U, provided that if R₁ is hydrogen, then X is CH-U, or if X is oxygen then R₁ is U;

DNK cont


- wherein U is hydrogen, O-(C1-C4)-straight or branched alkyl or O-(C2-C4)-straight or branched alkenyl, C1-C6-straight or branched alkyl, or C2-C6-straight or branched alkenyl, C5-C7-cycloalkyl or (C5-C7)-cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; and

- wherein J is hydrogen or C1 or C2 alkyl or benzyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylethyl; or wherein J and K may be taken together to form a 5 membered heterocyclic ring which may contain an oxygen (O), sulfur (S), SO or SO₂ substituted therein.

- D4*
41. A method for stimulating neurite outgrowth by a nerve cell, comprising:
administering to said nerve cell an effective amount of compound having an affinity for FKBP-type immunophilins according to formula II

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP


1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com



Formula II

or a pharmaceutically acceptable salt thereof,

- wherein Y is O, NH, or N-(C1-C4 alkyl);
- wherein Z is hydrogen, CHL-Ar, (C1-C6)-straight or branched alkyl, (C2-C6)-straight or branched alkenyl, (C5-C7)-cycloalkyl, (C5-C7)-cycloalkenyl or Ar substituted (C1-C6)-alkyl or (C2-C6)-alkenyl, or



- wherein L and Q are independently hydrogen, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl;
- wherein T is Ar or substituted cyclohexyl with substituents at positions 3 and 4 which are independently selected from the group consisting of hydrogen, hydroxyl, O-(C1-C4)-alkyl or O-(C2-C4)-alkenyl and carbonyl;
- wherein Ar is selected from the group consisting of 1-naphthyl, 2-naphthyl, 2-furyl, 3-furyl, 2-thienyl, 2-pyridyl, 3-pyridyl, 4-pyridyl and phenyl having one to three substituents which are independently selected from the

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com

group consisting of hydrogen, halo, hydroxyl, nitro, CF₃, (C1-C6)-straight or branched alkyl or (C2-C6)-straight or branched alkenyl, O-(C1-C4)-straight or branched alkyl or O-(C2-C4)-straight or branched alkenyl, O-benzyl, O-phenyl, amino and phenyl;

- wherein R₁ is U; X is either oxygen or CH-U, provided that if R₁ is hydrogen, then X is CH-U, or if X is oxygen then R₁ is U;

- wherein U is hydrogen, O-(C1-C4)-straight or branched alkyl or O-(C2-C4)-straight or branched alkenyl, C1-C6-straight or branched alkyl, or C2-C6-straight or branched alkenyl, C5-C7-cycloalkyl or (C5-C7)-cycloalkenyl substituted with (C1-C4)-straight or branched alkyl or (C2-C4)-straight or branched alkenyl, 2-indolyl, 3-indolyl, [(C1-C4)-alkyl or (C2-C4)-alkenyl]-Ar or Ar; and

- wherein J is hydrogen or C1 or C2 alkyl or benzyl; K is (C1-C4)-straight or branched alkyl, benzyl or cyclohexylethyl; or wherein J and K may be taken together to form a 5 membered heterocyclic ring which may contain an oxygen (O), sulfur (S), SO or SO₂ substituted therein.

REMARKS

With entry of this Amendment, claims 1-7, 11-15, 25-29, 33-37, 41-45, and 49 are pending in this application. Applicants have cancelled claims 8-10, 16-24, 30-32, 38-40, and 46-48 without prejudice to or disclaimer of the subject matter recited therein. Applicants have amended claims 1, 25, 33, and 41 to recite that J and K may be taken together to form a 5 membered heterocyclic ring. Support for this amendment may

FINNEGAN
HENDERSON
FARABOW
GARRETT &
DUNNER LLP

1300 I Street, NW
Washington, DC 20005
202.408.4000
Fax 202.408.4400
www.finnegan.com